Mass spectrometry for translational proteomics: progress and clinical implications
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerNetwork-Based Protein Biomarker Discovery PlatformsBeyond model antigens: high-dimensional methods for the analysis of antigen-specific T cellsRecent advances in mass spectrometry-based proteomics of gastric cancerHands-on workshops as an effective means of learning advanced technologies including genomics, proteomics and bioinformaticsMolecular portraits: the evolution of the concept of transcriptome-based cancer signaturesA novel spectral library workflow to enhance protein identificationsGhost peaks observed after atmospheric pressure matrix-assisted laser desorption/ionization experiments may disclose new ionization mechanism of matrix-assisted hypersonic velocity impact ionizationAntigenicity of Bovine Pericardium Determined by a Novel Immunoproteomic ApproachSimulation of electric potentials and ion motion in planar electrode structures for lossless ion manipulations (SLIM)Bayesian proteoform modeling improves protein quantification of global proteomic measurements.Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis.Biomarker discovery in mass spectrometry-based urinary proteomics.Large-Scale and Deep Quantitative Proteome Profiling Using Isobaric Labeling Coupled with Two-Dimensional LC-MS/MS.Genomics and proteomics: how long do we need to reach clinical results?Higher throughput methods of identifying T cell epitopes for studying outcomes of altered antigen processing and presentationProteomic analysis of protein purified derivative of Mycobacterium bovis.Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.Discovery of nutritional biomarkers: future directions based on omics technologies.Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential.A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease.Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.Simultaneous Proteomic Discovery and Targeted Monitoring using Liquid Chromatography, Ion Mobility Spectrometry, and Mass Spectrometry.Plasma Biomarker Identification and Quantification by Microparticle Proteomics.Proteomics Analysis of Circulating Serum Exosomes.Multiplexed panel of precisely quantified salivary proteins for biomarker assessment.Utilizing Ion Mobility to Identify Isobaric Post-Translational Modifications: Resolving Acrolein and Propionyl Lysine Adducts by TIMS Mass SpectrometryThe use of in-strip digestion for fast proteomic analysis on tear fluid from dry eye patients
P2860
Q26738703-7C9B35F1-CDB5-4D1B-B971-4437BC475748Q26751123-CB10D9BC-3A7F-4BA5-A0E4-740DE149B2B3Q27013972-6F552FDD-700F-49A6-8E33-1EB1180DF783Q28075514-29AB8B87-0B6C-4930-8B73-1F9DE999832AQ28387396-260266AD-E9F2-4CF1-9136-0474F86F325DQ28607220-4CDBA0E6-EECD-4AF0-843B-3511D8DBA7B4Q30542432-6C5AD4DD-754A-4F40-9204-195998517F53Q33465676-A25F2EBC-D355-4A4A-8914-FCC45C32A16EQ33732798-273DA20D-5260-4E76-868C-C942AEB46C3DQ34345000-8A59DF1A-38C8-4B76-AA17-85AB180E2A5EQ34635023-3E23D793-29C8-484F-AE36-307DB714315EQ35452689-40E1FD2B-241E-45A8-9175-ABA1DD5D43C5Q36956324-370F6675-97F2-4A25-8656-6EF515D5AFCCQ37626041-F9C86E6A-38E4-487A-97FC-E1DBDE47D2B2Q38111944-13C26F67-2A7A-4006-9466-B3B09985FB70Q38173752-BDBCC433-78DE-40F8-A382-790076A8E9F1Q38378581-EF3CCF04-AA28-463F-88AA-ADB8910644A7Q38384848-080B5A3A-37DE-40B8-8356-6D50573E4838Q38560461-6D02AAA6-C5E0-46A2-9BCF-EFDDE74BB351Q39657160-8C6A93D5-BDB0-485C-B72B-8FF46A507758Q42684122-93B8C0CC-3DCC-438B-8A4F-613E7DEBBEBCQ45072735-4524BF04-C06D-4D84-9775-24D6C26275AAQ45348524-121C42B5-C782-4887-AEAD-A051F84D98E7Q50908853-E9F71EE7-109D-4F15-AB0E-8548C6F2281AQ50908913-B85AA7A9-B49A-4F2B-83F3-5F3A233302E9Q51564069-FA0B014F-C494-462B-8EF4-CBBFBDDC4DFDQ58128325-DF579C05-97F0-4C37-8CB6-371DC195CD2FQ58802532-79FDB885-2FD1-465D-B22B-F0BE1D402BA2
P2860
Mass spectrometry for translational proteomics: progress and clinical implications
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mass spectrometry for translational proteomics: progress and clinical implications
@ast
Mass spectrometry for translational proteomics: progress and clinical implications
@en
Mass spectrometry for translational proteomics: progress and clinical implications
@nl
type
label
Mass spectrometry for translational proteomics: progress and clinical implications
@ast
Mass spectrometry for translational proteomics: progress and clinical implications
@en
Mass spectrometry for translational proteomics: progress and clinical implications
@nl
prefLabel
Mass spectrometry for translational proteomics: progress and clinical implications
@ast
Mass spectrometry for translational proteomics: progress and clinical implications
@en
Mass spectrometry for translational proteomics: progress and clinical implications
@nl
P2860
P50
P3181
P356
P1433
P1476
Mass spectrometry for translational proteomics: progress and clinical implications
@en
P2093
Gordon A Anderson
Yehia M Ibrahim
P2860
P2888
P3181
P356
10.1186/GM364
P407
P577
2012-01-01T00:00:00Z
P5875
P6179
1047384517